Literature DB >> 24188703

Antibody-based concepts for multipurpose prevention technologies.

Kevin J Whaley1, Larry Zeitlin.   

Abstract

Because of the versatility and specificity of monoclonal antibodies, they are candidates for multipurpose prevention technologies when formulated as topical (gels, films, rings) or injectable drugs and as vaccines. This review focuses on antibody-based proof of concept studies for the human immunodeficiency virus, herpes simplex virus and sperm. Opportunities and challenges in antibody evasion/resistance, manufacturing, regulatory, and pharmacoeconomics are discussed. This article is based on a presentation at the "Product Development Workshop 2013: HIV and Multipurpose Prevention Technologies," held in Arlington, Virginia on February 21-22, 2013. It forms part of a special supplement to Antiviral Research.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Herpes simplex virus; Human immunodeficiency virus; Multi-antibody; Multipurpose prevention technologies; Sperm

Mesh：

Substances：

Year:  2013        PMID： 24188703      PMCID： PMC3933545          DOI： 10.1016/j.antiviral.2013.09.027

Source DB:  PubMed          Journal:  Antiviral Res        ISSN： 0166-3542            Impact factor:   5.970


  62 in total

Review 1.  Targeting Trojan Horse leukocytes for HIV prevention.

Authors:  Deborah J Anderson; Joseph A Politch; Adam M Nadolski; Caitlin D Blaskewicz; Jeffrey Pudney; Kenneth H Mayer
Journal:  AIDS       Date:  2010-01-16       Impact factor: 4.177

2.  Characterization of a type-common human recombinant monoclonal antibody to herpes simplex virus with high therapeutic potential.

Authors:  A De Logu; R A Williamson; R Rozenshteyn; F Ramiro-Ibañez; C D Simpson; D R Burton; P P Sanna
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

Review 3.  Monoclonal antibodies for reproductive health: Part I. Preventing sexual transmission of disease and pregnancy with topically applied antibodies.

Authors:  R A Cone; K J Whaley
Journal:  Am J Reprod Immunol       Date:  1994-09       Impact factor: 3.886

4.  A neonatal Fc receptor-targeted mucosal vaccine strategy effectively induces HIV-1 antigen-specific immunity to genital infection.

Authors:  Li Lu; Senthilkumar Palaniyandi; Rongyu Zeng; Yu Bai; Xindong Liu; Yunsheng Wang; C David Pauza; Derry C Roopenian; Xiaoping Zhu
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

5.  Contraceptive effect of sperm-agglutinating monoclonal antibodies in rabbits.

Authors:  P E Castle; K J Whaley; T E Hoen; T R Moench; R A Cone
Journal:  Biol Reprod       Date:  1997-01       Impact factor: 4.285

6.  Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L.

Authors:  Ann J Hessell; Eva G Rakasz; David M Tehrani; Michael Huber; Kimberly L Weisgrau; Gary Landucci; Donald N Forthal; Wayne C Koff; Pascal Poignard; David I Watkins; Dennis R Burton
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

7.  Enhanced antibody half-life improves in vivo activity.

Authors:  Jonathan Zalevsky; Aaron K Chamberlain; Holly M Horton; Sher Karki; Irene W L Leung; Thomas J Sproule; Greg A Lazar; Derry C Roopenian; John R Desjarlais
Journal:  Nat Biotechnol       Date:  2010-01-17       Impact factor: 54.908

8.  Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure.

Authors:  Richard Strasser; Johannes Stadlmann; Matthias Schähs; Gabriela Stiegler; Heribert Quendler; Lukas Mach; Josef Glössl; Koen Weterings; Martin Pabst; Herta Steinkellner
Journal:  Plant Biotechnol J       Date:  2008-03-13       Impact factor: 9.803

9.  Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model.

Authors:  Milena Veselinovic; C Preston Neff; Leila R Mulder; Ramesh Akkina
Journal:  Virology       Date:  2012-07-24       Impact factor: 3.616

10.  Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus.

Authors:  L A Lagenaur; B E Sanders-Beer; B Brichacek; R Pal; X Liu; Y Liu; R Yu; D Venzon; P P Lee; D H Hamer
Journal:  Mucosal Immunol       Date:  2011-07-06       Impact factor: 7.313
View more
  5 in total

Review 1.  Long acting systemic HIV pre-exposure prophylaxis: an examination of the field.

Authors:  William R Lykins; Ellen Luecke; Daniel Johengen; Ariane van der Straten; Tejal A Desai
Journal:  Drug Deliv Transl Res       Date:  2017-12       Impact factor: 4.617

2.  Commercially available immunoglobulins contain virus neutralizing antibodies against all major genotypes of polyomavirus BK.

Authors:  P Randhawa; D V Pastrana; G Zeng; Y Huang; R Shapiro; P Sood; C Puttarajappa; M Berger; S Hariharan; C B Buck
Journal:  Am J Transplant       Date:  2015-03-03       Impact factor: 8.086

Review 3.  Strategies for preventing mucosal cell-associated HIV transmission.

Authors:  Kevin J Whaley; Kenneth H Mayer
Journal:  J Infect Dis       Date:  2014-12-15       Impact factor: 5.226

4.  Pharmacokinetics and Preliminary Safety of Pod-Intravaginal Rings Delivering the Monoclonal Antibody VRC01-N for HIV Prophylaxis in a Macaque Model.

Authors:  Chunxia Zhao; Manjula Gunawardana; Francois Villinger; Marc M Baum; Mariana Remedios-Chan; Thomas R Moench; Larry Zeitlin; Kevin J Whaley; Ognian Bohorov; Thomas J Smith; Deborah J Anderson; John A Moss
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

5.  Herpes simplex virus-binding IgG traps HSV in human cervicovaginal mucus across the menstrual cycle and diverse vaginal microbial composition.

Authors:  Holly A Schroeder; Kenetta L Nunn; Alison Schaefer; Christine E Henry; Felix Lam; Michael H Pauly; Kevin J Whaley; Larry Zeitlin; Mike S Humphrys; Jacques Ravel; Samuel K Lai
Journal:  Mucosal Immunol       Date:  2018-07-09       Impact factor: 7.313
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.